In Alzheimer’s disease (AD), there is profound, selective degeneration of BFCN, which correlates with cognitive deficits and constitutes the basis of the “cholinergic hypothesis”, as well as the use of acetylcholinesterase inhibitors as symptomatic treatment [95,96,97]. This evidence concerns the gene ACHE and Alzheimer disease.